Summary
- Checkmate Pharmaceuticals has filed to raise $75 million in an IPO.
- The firm is developing a drug candidate for the treatment of various cancers.
- CMPI has shown promising early trial results and has enviable major pharma collaboration relationships.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Checkmate Pharmaceuticals (CMPI) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement.
The company is a clinical stage biopharma advancing a drug treatment candidate for melanoma and head & neck cancer.
CMPI has produced promising early trial results and has significant collaboration partnerships with major pharma firms.
I’ll provide a final opinion when we learn more about the IPO from management.
Company & Technology
Cambridge, Massachusetts-based Checkmate was founded to develop its CMP-001 candidate, a Toll-like receptor 9, TLR9 'agonist delivered as a biologic virus-like particle, or VLP.'
Management is headed by Barry Labinger, who has been with the firm since December 2018 and was previously president and CEO of Biothera Pharmaceuticals, a clinical stage cancer immunotherapy company.
Below is a brief overview video of skin cancers:
